2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, MPN, CML, Study Population, Human, Adult, Animal Model
PAPER

3733 Analytical precision, linearity, and two-site reproducibility of a single molecule counting PCR assay for BCR::ABL1 monitoring in chronic myeloid leukemia

Jerald Radich, MD, alex Zevin, PhD2, Lan Beppu3, Olga Sala-Torra, MD4, Jeanette Mei5, Jung won Keum6, Christina Fan7, Namrata Pabbati8, Eleen Shum, Ph.D9
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Countable Labs, Palo Alto, California, United States
6 Countable Labs, Palo Alto, California, United States
7 Countable Labs, Palo Alto, California, United States
8 Countable Labs, Palo Alto, California, United States
9 Countable Labs, Palo Alto, California, United States
Background

Quantification of BCR::ABL1 transcripts on the International Scale (IS) is central to response monitoring and measurable residual disease (MRD) detection in chronic myeloid leukemia (CML). Sensitive detection of BCR::ABL1 is especially important in determining which CML patients which may be suitable for TKI discontinuation.  We evaluated a single molecule counting PCR assay (Countable PCR) that directly counts BCR::ABL1 and ABL1 molecules from RNA in a single workflow, across two independent laboratories.

Methods

Countable PCR BCR::ABL1 is a single-well multiplex assay that simultaneously detects and quantifies the common p210 (e14a2, e13a2) and p190 (e1a2) transcripts, plus p230 (e19a2), alongside ABL1 in one reaction. Quantification uses direct digital counting of each amplified molecule to yield absolute BCR::ABL1/ABL1 ratios without standard curves, Ct values, Poisson estimation, or calibration to external standards. Analytical sensitivity extends to MR4.5.

To preserve transcript integrity during inter-site sample transport, this reproducibility study was evaluated to MR3. Identical reagent lots and co-prepared sample aliquots were split and run at Fred Hutchinson Cancer Center (Site 1) and Countable Labs (Site 2). Component 1 (single-site precision, Site 1): InvivoScribe BCR::ABL1 RNA dilution sets for e1a2 (p190) and e14a2 (p210) at three 10-fold levels (L1–L3); 4 replicates/day over 2 days (n=8/level); percent ratio (BCR::ABL1/ABL1%) computed after isoform calling. Component 2A (two-site reproducibility): ThermoFisher AcroMetrix BCR::ABL1 %IS Reference Panel (e14a2) at three levels spanning ~MR1–MR3 (vendor 10–15%, 1–2%, and 0.1–0.2% IS); 4 replicates/site/day over 2 days (n=8/site). Linearity was assessed by log–log regression.

Results

Component 1 (single-site precision; n=8) yielded pooled coefficients of variation (CV) ≤8.8% across both isoforms and all three levels: e1a2 5.9% (MR1), 6.1% (MR2), 3.6% (MR3); e14a2 8.8% (MR1), 7.2% (MR2), 2.8% (MR3). Dilution linearity was calculated across the three 10-fold levels for both isoforms (slope 0.94; R² = 0.9997 for e1a2 and 0.9996 for e14a2). Component 2A spanned ~MR1–MR3 and mean BCR::ABL1% IS ratios were concordant between Fred Hutch and Countable Labs at every level (MR1 8.42% vs 8.06%; MR2 0.93% vs 0.84%; MR3 0.07% vs 0.06%). Between-site CVs were 3.1% (MR1), 7.7% (MR2), and 8.3% (MR3). In a single center at the MR3 level, the Fred Hutchinson Cancer Center site between-day CV was 0.0% across 8 replicates.

Conclusions The Countable BCR::ABL1 assay demonstrated high analytical precision, strong linearity, and excellent two-site reproducibility (CV ≤8.3%), with distinct advantages over existing PCR and digital PCR systems. Because ratios derive from true absolute molecule counting rather than amplification-curve estimation, raw BCR::ABL1/ABL1 ratios closely tracked %IS values and remained concordant between sites without inter-laboratory calibration. This raises the possibility that an inherently quantitative, lab-independent counting method could ease the reliance on external standardization that legacy qPCR requires to manage its variability. Multiplexing p210, p190, and p230 alongside ABL1 in a single well without compromising sensitivity may also broaden the range of patients monitorable on one assay.

Jerald Radich, MD: thermofisher - Honoraria; azurity - Honoraria; Novartis - Honoraria; ascent age - Honoraria; servier - Honoraria